Cifin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cifin

Understanding Cifin

Cifin is a pharmaceutical medication belonging to the fluoroquinolone class of antibiotics. It is formulated to address various bacterial infections by interfering with the ability of bacteria to replicate and repair their genetic material. This mechanism of action helps the body's immune system manage and clear the infection.

Therapeutic Purpose

As an antibacterial agent, Cifin is used to treat a range of conditions caused by susceptible strains of bacteria. It is commonly utilized for infections affecting the following areas:

  • Urinary Tract: Including both uncomplicated and complicated infections of the bladder and kidneys.
  • Respiratory System: Such as certain types of pneumonia or flare-ups of chronic bronchitis.
  • Skin and Soft Tissue: Infections involving the skin layers or underlying structures.
  • Bones and Joints: Specific bacterial infections that affect the skeletal system.
  • Gastrointestinal Tract: Including certain types of infectious diarrhea.

How It Functions

The active component in Cifin targets specific enzymes within bacterial cells known as DNA gyrase and topoisomerase IV. These enzymes are essential for the bacteria to coil and uncoil their DNA during reproduction. By inhibiting these enzymes, the medication prevents the bacteria from multiplying, which leads to the eventual reduction and elimination of the bacterial population in the body. It is important to note that Cifin is effective only against bacterial infections and does not have an effect on viral infections such as the common cold or influenza.

Regulatory References

  1. NIH StatPearls on Ciprofloxacin
  2. WHO Essential Medicines List

What side effects are possible with Cifin?

Possible side effects and safety information

The safety profile of Cifin (Ciprofloxacin) is formally documented by government regulatory agencies and is classified by frequency and system-organ class. The most Common adverse reactions listed in official prescribing information include nausea and diarrhea. Other commonly documented effects fall into the gastrointestinal, nervous system, and dermatological categories.


Serious and Potentially Irreversible Adverse Reactions

Regulatory documents emphasize the risk of Serious Adverse Reactions that can be disabling and potentially irreversible. These include disorders of the Musculoskeletal and Connective Tissue, such as tendinitis and tendon rupture, and damage to the Nervous System, specifically peripheral neuropathy.

Additionally, the official safety documentation highlights risks related to the Cardiac System, such as QT interval prolongation and Torsade de pointes, and severe immune responses, including anaphylaxis.


Safety Considerations by Population and Timing

Official labeling contains specific Population-Specific Safety Notes.

Population Safety Consideration
Older Adults Increased risk of severe tendon disorders.
Pediatric Patients Use is restricted due to potential for musculoskeletal disorders.

Some serious effects, such as tendon rupture, may occur not only during treatment but also months after discontinuing the medicine, while peripheral neuropathy can manifest rapidly following initiation. Cifin is contraindicated in individuals with a known hypersensitivity to any fluoroquinolone and co-administration with Tizanidine. The safety profile requires caution for patients with a history of cardiac arrhythmia or pre-existing tendon disorders.

Overdose and Emergency Response

The official regulatory profile for Cifin overdosage focuses on the potential for acute organ toxicity and the mandated emergency response. Reports following acute overdosage have documented the occurrence of reversible renal toxicity, establishing the renal system as the primary physiological area of concern within the regulatory labels.

In the event of suspected or known acute overdosage, immediate medical assistance is strictly required. Patients must seek emergency medical attention promptly, as explicitly stated in the regulatory guidance. The mandated emergency-response includes placing the patient under careful observation and initiating supportive treatment.

Since no specific antidote is known, management is constrained to symptomatic and procedural support. Official guidance specifies that adequate hydration must be maintained, and routine monitoring of renal function is a critical component of post-overdose care. The label also notes that procedural removal methods like hemodialysis or peritoneal dialysis are limited, typically removing only a small amount of the active ingredient. This regulatory classification confirms that any overdose scenario necessitates urgent intervention and specialized clinical monitoring.

Therapeutic Uses of Cifin

What Cifin Treats: Main Uses and Benefits

Cifin is used in situations involving certain distressing symptoms linked to infections, applied across domains where additional symptomatic support is needed. Its use is considered relevant in contexts involving heightened systemic burden where supportive symptom management is appropriate. The medication is commonly used to help manage symptoms associated with bacterial infections of the urinary tract, skin, respiratory system, and digestive tract.

When applied in clinical settings that involve acute or unstable symptom patterns, it supports the patient during difficult episodes and helps maintain a sense of stability when symptoms are more noticeable. The overall therapeutic goal is to address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.

“It provides support that helps ease the overall symptom burden.”

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

The medication is relevant for managing symptoms that interfere with daily comfort, such as localized pain and burning. It is commonly used across conditions presenting with acute episodes.

Eligibility and Restrictions for Use

The eligibility for Cifin (ciprofloxacin) is strictly defined by government regulatory documents, which establish specific populations who may use the medicine and those who are formally excluded.

Populations Who Must Not Use Cifin (Contraindications)

Official labeling mandates that Cifin is contraindicated and must not be used in patients under the following conditions:

  • Known Hypersensitivity: Individuals with a known allergy or severe reaction to ciprofloxacin, any other quinolone or fluoroquinolone antibacterial, or any component of the formulation.
  • Concomitant Tizanidine Use: Patients who are simultaneously taking the muscle relaxant drug tizanidine (Zanaflex).

Eligibility Restrictions and Special Considerations

Other patient groups require avoidance or special evaluation due to potential risk or lack of established safety:

  • Myasthenia Gravis: Use must be avoided in patients with a known history of this neuromuscular disorder due to the risk of muscle weakness exacerbation.
  • Age-Related Rules: Cifin is generally not recommended for children and growing adolescents (under 18 years) due to risk of joint damage, except for specific, severe infections like Complicated Urinary Tract Infections (cUTI), Pyelonephritis, Inhalational Anthrax, or Plague, where use is explicitly approved.
  • Pregnancy and Lactation: Use is generally not recommended or is reserved for severe infections where no alternative treatment is available.
  • Renal Impairment: Patients with reduced kidney function require a dose adjustment based on their degree of impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cifin (ciprofloxacin) may interact with various medicinal products and supplements, requiring special precautions or monitoring.

Contraindicated Combination

  • Tizanidine: Co-administration with Tizanidine (a muscle relaxant) is not permitted due to the risk of severe side effects, including dangerously low blood pressure and excessive drowsiness.

Interactions Requiring Close Monitoring or Dose Adjustment

Interacting Product Category Potential Effect & Management
Theophylline and certain CYP1A2 substrates (e.g., Ropinirole) Cifin can significantly increase blood levels of these drugs, raising the risk of serious or fatal adverse effects. Serum levels must be closely monitored.
Warfarin (blood thinner) The anticoagulant effect is enhanced, leading to an increased risk of bleeding. Prothrombin time and INR must be frequently monitored.
Antidiabetic Agents (e.g., Glyburide) May cause disturbances in blood glucose, including the risk of severe hypoglycemia. Blood sugar levels must be monitored closely.
QT-Prolonging Drugs (e.g., certain Antiarrhythmics, Antidepressants) Increased risk of heart rhythm problems, including QT interval prolongation. Concomitant use should be avoided.
Multivalent Cation-Containing Products (e.g., Antacids, Sucralfate, Mineral Supplements, Dairy) These products can bind to Cifin in the stomach, dramatically reducing its absorption and effectiveness. Oral Cifin must be taken at least 2 hours before or 6 hours after these products.
Cyclosporine, Methotrexate, Phenytoin Cifin may alter the body's concentrations of these medicines. Levels should be monitored, and dose adjustments may be needed.

Mechanism of Action

Interference with Bacterial Genetic Material

Cifin's action centers on the core process of bacterial DNA replication and repair by acting as a targeted inhibitor. The compound binds selectively to and disrupts the function of two bacterial enzymes, DNA gyrase and Topoisomerase IV, which are vital for unwinding and maintaining the integrity of the bacterial chromosome . This engagement initiates a molecular cascade that leads directly to the irreversible loss of viability in the targeted cells.


Cascade of Cellular Termination

The mechanism involves more than simple inhibition; by stabilizing the DNA-enzyme complex, Cifin causes double-strand breaks in the bacterial DNA. This resulting accumulation of irreparable genetic damage leads to the rapid loss of cellular viability, which is a physiological outcome that terminates the cell's function. This core mechanism is selective, primarily targeting these specific enzymes within the bacterial pathway, contributing to the drug's physiological effect of causing widespread cell death among susceptible bacterial organisms.

Dosage and Administration Information

How to Use Cifin: Official Administration Guidelines

Cifin, containing the active ingredient Ciprofloxacin, is administered via several officially approved routes, including oral (tablets and suspension), intravenous (IV), and specialized topical drops (ophthalmic/otic). Dosing, frequency, and duration are strictly determined by specific infection characteristics and established protocols.


Administration and Timing

Type Dosage Frequency Administration Instructions
Immediate-Release (Oral/IV) Typically Twice Daily (q12hr). In severe cases, IV dosing may be Every 8 Hours (q8hr). Can be taken with or without food. Extended-Release (XR) tablets must be swallowed whole.
Extended-Release (Oral) Once Daily (q24hr). Must be separated from multivalent cation-containing products (e.g., antacids, iron, calcium supplements) by at least 2 hours before or 6 hours after the Cifin dose.

Procedural Rules and Adjustments

Official guidelines require specific procedural adherence for proper use:

  • Preparation: The oral suspension must be shaken vigorously for 15 seconds before measuring. IV solutions must be administered as a slow infusion over 60 minutes.
  • Fluid Intake: Patients are instructed to drink plenty of fluids to aid proper elimination.
  • Missed Dose: If a regular dose is missed, it should be taken as soon as remembered, unless the next dose is due within 6 hours (for standard tablets/suspension) or 8 hours (for XR tablets), in which case the missed dose should be skipped.
  • Dose Modification: A dose adjustment is mandatory for adult patients with reduced Creatinine Clearance (CrCl 50 mL/min). Dosing for children is calculated based on body weight (mg/kg), with a defined maximum per dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on the Combined Ingredients

Studies have investigated the combination of Glucosamine Sulfate (GS) and Chondroitin Sulfate (CS) across diverse patient populations. Both ingredients have been the subject of numerous clinical trials and meta-analyses exploring their use in managing symptoms associated with joint discomfort.

  • Glucosamine Sulfate (GS): Research has examined this ingredient in studies focusing on joint function and assessed outcomes related to inflammation.
  • Chondroitin Sulfate (CS): CS has been examined in clinical trials in relation to reported pain and mobility outcomes, and research has explored its potential role in the components of cartilage.

Clinical Trial Findings and Outcomes

The effects of the combination have been analyzed in systematic reviews and meta-analyses of Randomized Controlled Trials (RCTs). These studies reported a change in measured joint discomfort scores over observation periods, such as 24 weeks.

Measured Outcome Typical Study Endpoint Reported Finding (Meta-Analysis)
Symptom Change WOMAC or VAS Pain Score Reported change in scores over 6 months of use
Physical Function Walking speed, ADL performance Studies evaluated participant-reported improvements in mobility

Most trials utilized a double-blind, placebo-controlled design and included adult participants, typically aged 45 to 75, with mild to moderate joint-related symptoms. Long-term follow-up studies, including observational research, have explored the effects of continuous use over periods of up to two years.

Safety and Tolerability Profile

Safety data was collected across all included studies. The results suggested that the medication was generally tolerated over the study duration. The most frequently reported adverse events were mild and primarily related to the gastrointestinal system, such as minor nausea or indigestion. No serious adverse events were consistently attributed to the study medication.

Key Studies & References The Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT): design, rationale, and methods

Frequently Asked Questions (FAQ)

Common questions about Cifin (FAQ)

Q: How quickly should I expect Cifin to start working?

Official studies focusing on the drug's activity indicate that Cifin is absorbed rapidly after an oral dose, with the highest concentration in the bloodstream typically occurring within 1 to 2 hours. The medicine's elimination from the body, known as its half-life, is approximately 4 hours after an intravenous dose. This indicates the rate at which the drug enters the bloodstream, though the actual time until symptoms improve varies widely based on the specific infection being treated.

Q: Why does my doctor call it something different sometimes?

Cifin is the commercial or brand name for the medicine. According to official documents, the active ingredient is Ciprofloxacin. Healthcare professionals and pharmacies often use the official, non-proprietary name, Ciprofloxacin, to refer to the drug.

Q: Can Cifin be used for conditions other than what's listed?

The official labeling defines specific infections and conditions for which the drug has been approved by regulatory agencies. When used, the drug is generally prescribed only for the conditions listed in the official Indications and Usage sections.

Q: What happens if I miss a dose of Cifin?

Regulatory guidelines state that if a dose is missed, it should be taken as soon as it is remembered. However, if the time is almost right for the next scheduled dose, the missed dose should be skipped entirely. This guideline is in place to help avoid taking doses too closely together.

Q: Is it normal to feel a minor, general symptom like fatigue or mild headache when starting Cifin?

According to official adverse reaction data, minor side effects such as headache are listed as common when taking Cifin. Other common, non-specific symptoms that have been reported include dizziness and nausea.

Q: Can I drink alcohol while taking Cifin?

Official documents do not typically list alcohol as a formal contraindication. However, some authoritative sources note that caution or limitation of alcohol intake may be appropriate because of a potential for increased or worsened side effects, such as dizziness or central nervous system effects.

Q: What foods should I avoid when I'm on Cifin?

Official guidance indicates that concurrent use of Cifin with dairy products such as milk or yogurt, or with beverages fortified with minerals like calcium, should be avoided because absorption of the medicine may be reduced. Regulatory guidelines state that taking the drug with a meal that contains these products is generally permitted.

Q: Can Cifin affect my sleep?

Yes, official prescribing information lists insomnia (trouble sleeping) as a documented Central Nervous System (CNS) effect that has been reported by users of Cifin.

Q: Does Cifin cause weight gain or weight loss?

Weight change is not consistently listed as a common or serious adverse reaction in the official regulatory documents or prescribing information for Cifin.

Q: Is Cifin a controlled substance?

Ciprofloxacin, the active ingredient in Cifin, is formally classified as a Prescription Only Medicine (℞-only) in many regions. However, it is not classified as a controlled substance that is subject to specialized restrictions related to dependence.

Q: How long does Cifin stay in your system?

The time the medicine persists is indicated by its elimination half-life, which is approximately 4 hours. Based on this pharmacokinetic data, most of the administered dose of the medicine is typically eliminated from the body within about 24 hours after the last dose.

Q: What is the risk of dependence or withdrawal with Cifin?

Regulatory documents warn against stopping the medication prematurely due to the risk of ineffective treatment. However, dependence and significant physical withdrawal symptoms are generally not listed in the safety information for this type of drug.

Q: Is Cifin safe for older adults (seniors)?

Official regulatory labeling includes specific warnings for older adults, noting that they have an increased risk of severe tendon disorders. For this reason, dosage decisions often include consideration of the patient's age and overall kidney function.

Q: Can children or teenagers use Cifin?

The use of Cifin is generally not recommended for children and growing adolescents under the age of 18 due to the potential risk of joint damage. Its use is approved only for specific, severe infections, such as complicated urinary tract infections or exposure to anthrax, where alternatives are not suitable.

Q: Are there any specific vitamins or supplements that interact with Cifin?

Official documents advise specific caution regarding the simultaneous use of Cifin with mineral supplements. These include products containing multivalent cations like calcium, iron, magnesium, or zinc, as they can significantly reduce the drug's absorption and effectiveness.

Q: Does Cifin affect fertility in men or women?

Current authoritative literature does not include human studies that definitively establish whether Cifin can affect fertility in men or women.

Q: Is it okay to stop taking Cifin suddenly?

Regulatory information includes statements that patients should avoid stopping the medicine suddenly without consultation with a healthcare professional. Stopping treatment too soon may risk the infection not being completely eradicated, which can increase the risk of antibiotic resistance.

Q: What is the expiration time for Cifin once the bottle is opened?

The manufacturer's official monograph specifies storage conditions for the product after it has been prepared. For the oral suspension, for example, a specific shelf-life, such as 14 to 30 days, is required after reconstitution, depending on the exact formulation and storage temperature.

Q: Are there any known genetic factors that affect how Cifin works?

Authoritative research has focused on genetic factors in the target bacteria that can cause resistance to Cifin. However, specific human genetic factors that affect the drug's action are not typically detailed in general patient-facing regulatory materials.

Q: What happens if Cifin stops working for me?

Official warnings note that if doses are skipped or treatment is stopped prematurely, this can increase the risk of the infection becoming resistant to the medication. This would result in the drug becoming less effective, and a healthcare professional would need to be consulted.

Q: Does Cifin affect blood sugar levels?

Yes. The drug is officially known to cause disturbances in blood glucose, including the risk of hypoglycemia (low blood sugar) and, less frequently, high blood sugar. This is a documented side effect.

Q: What should I do if Cifin makes me feel dizzy or lightheaded?

Regulatory documents describe that when the medicine causes dizziness, official guidance includes advice to sit up or stand slowly. This information is intended to describe methods to manage the risk of dizzy or fainting spells.

Q: Can I drive or operate machinery while taking Cifin?

Official labeling states that Cifin can cause side effects like dizziness and lightheadedness, which may impair judgment. Official labeling includes statements that patients should refrain from driving, operating machinery, or performing other activities requiring mental alertness or coordination until they have observed how the medicine affects their functioning.

Q: Is Cifin considered a 'new' drug or has it been around for a long time?

The active ingredient in Cifin, Ciprofloxacin, was initially approved by the FDA in 1987. This indicates that it has been an established treatment for a relatively long period and is included on the World Health Organization's Model List of Essential Medicines.

Q: Does Cifin interact with common over-the-counter pain relievers?

Official documents list specific nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen as potentially interacting with Cifin. It is important to review the full interaction list with a healthcare provider.

Q: Does my body build up a tolerance to Cifin over time?

The official documentation does not use the term 'tolerance' in a human context. However, regulatory sources caution that incomplete or premature treatment can lead to the development of drug-resistant bacteria, which could mean that the drug may become ineffective against the specific organism causing the infection.

Q: Is there a maximum time someone can take Cifin according to the manufacturers?

The duration of therapy is highly specific and dictated by the type of infection being treated. While some treatments may last only 3 days, others, such as those for anthrax prophylaxis, are specified for 60 days. There is no single universal maximum duration.

Q: What is the typical duration of treatment with Cifin?

The duration of treatment is determined by the specific infection and its severity. Official dosing guidelines provide examples ranging from 3 to 14 days for common infections like urinary tract infections, to 4 to 8 weeks for more serious conditions like bone and joint infections.

Q: Are there alternative treatment options to Cifin discussed in medical literature?

The official Summary of Product Characteristics (SmPC) states that for certain uncomplicated conditions, Cifin should be considered only when the use of other commonly recommended antibacterial agents is inappropriate, indicating that a range of alternative treatments exists.

Q: Does Cifin affect blood pressure?

The medicine is contraindicated for use with the drug Tizanidine due to the risk of severe low blood pressure (hypotension). While changes in heart rhythm are documented serious adverse events, Cifin is not generally listed as causing a common, direct effect on blood pressure in the general patient population.

Q: Is Cifin ever used in combination with other drugs for the main condition?

Yes. Official documents state that for specific severe or mixed infections, such as complicated intra-abdominal infections, Cifin should be co-administered with other appropriate antimicrobial agents to ensure complete treatment.

Q: If I have allergies, can I still take Cifin?

Cifin is formally contraindicated if a patient has a known allergy or severe reaction to ciprofloxacin or any other drug belonging to the quinolone or fluoroquinolone class of antibiotics.

Q: Can Cifin cause mental health side effects, such as anxiety or depression?

Yes. Official warnings for Cifin include serious Central Nervous System effects such as anxiety, depression, confusion, and hallucinations. These side effects are documented to occur, sometimes shortly after starting the medicine.

How should Cifin be stored and disposed of?

Official Storage and Disposal Requirements for Cifin

Cifin must be stored at controlled room temperature, typically maintained between 20°C and 25°C (68°F and 77°F), as designated by official regulatory labeling. It is mandatory to keep the product in its original, tightly sealed container to ensure protection from excessive moisture and light. Explicit warnings, such as "Do not freeze," must be strictly followed to preserve the drug's stability and efficacy.

Stability and Handling

Adhere to the expiration date printed on the container. If Cifin requires reconstitution, specific in-use stability periods and associated storage conditions for the prepared solution are defined in the labeling. Always store Cifin out of the reach of children, often requiring the use of child-resistant packaging.

Disposal Protocol

Unused or expired Cifin must be disposed of according to official regulatory guidance. Patients should utilize authorized drug take-back programs or follow specific at-home disposal instructions provided by the manufacturer or governmental authorities, avoiding disposal through sinks or toilets unless explicitly directed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cifin found in:

A-Z Index: